TG Therapeutics, Inc. (TGTX) is riding high on Wednesday, with its stock surging after the company unveiled updated data from its Phase 3 trials for BRIUMVI (ublituximab-xiiy). This experimental drug is being evaluated as a potential treatment for individuals with relapsing forms of multiple sclerosis (MS).
The data, presented at the prestigious European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, paints a positive picture for BRIUMVI. It revealed that sustained use of the drug led to significant clinical benefits, including a continued decrease in annualized relapse rates. This means that patients treated with BRIUMVI experienced fewer relapses over time.
Specifically, the data showed that after three years, the annualized relapse rate was 3.2%. However, after five years of treatment, the rate dropped to a remarkable 2%. Furthermore, the data revealed that after five years of continuous treatment, a notable 17% of patients experienced confirmed disability improvement for at least 24 weeks. This is encouraging news for individuals with MS, as it signifies that BRIUMVI could potentially help slow or even reverse the progression of disability associated with the disease.
While the data showcased positive results, it is important to note that 8% of patients did experience confirmed disability progression for at least 24 weeks following five years of treatment. This highlights the need for ongoing research and monitoring to further understand the long-term impact of BRIUMVI.
On a positive note, the safety profile of BRIUMVI remained consistent over the five-year study period. This is a crucial factor for any long-term treatment, as it indicates that the drug is generally well-tolerated.
“These data demonstrate that patients treated with BRIUMVI for up to 5 years had sustained clinical benefit, including further reductions in the risk of relapse in later years of treatment and an impressively low rate of confirmed disability progression,” commented Michael Weiss, CEO and chairman of TG Therapeutics.
The positive data released by TG Therapeutics has ignited investor enthusiasm, propelling TGTX stock upwards. At the time of this writing, the stock is trading 1.52% higher at $25.46 per share.
This news underscores the potential of BRIUMVI as a promising treatment option for individuals living with relapsing forms of MS. As further research and clinical trials progress, it will be interesting to see how this drug might shape the future of MS treatment.
